How were Calyxt's earnings last quarter?

Calyxt, Inc. (NASDAQ:CLXT) announced its quarterly earnings results on Monday, May, 1st. The company reported ($5.45) EPS for the quarter, missing analysts' consensus estimates of ($3.00) by $2.45. The business had revenue of $0.04 million for the quarter. Calyxt had a negative net margin of 9,979.64% and a negative trailing twelve-month return on equity of 259.69%.

When did Calyxt's stock split?

Calyxt shares reverse split before market open on Thursday, June 1st 2023. The 1-5 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Calyxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calyxt investors own include Cellectis (CLLS) , Molecular Templates (MTEM) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , Corbus Pharmaceuticals (CRBP) , Cypress Semiconductor (CY) , Dynavax Technologies (DVAX) , GW Pharmaceuticals (GWPH) , Iovance Biotherapeutics (IOVA) and Invitae (NVTA) .

Calyxt (CLXT) raised $101 million in an IPO on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

NASDAQ:CLXT

Calyxt (CLXT) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free CLXT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $6.30
▼
$31.50
52-Week Range: N/A

Volume: 254,600 shs
Average Volume: 139,308 shs
Market Capitalization: $31.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Calyxt alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Calyxt Stock (NASDAQ:CLXT)

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

CLXT Stock News Headlines

May 20, 2023 | seekingalpha.com

Calyxt stockholders approve merger and reverse stock split; anticipated name change and ticker symbol for combined company

May 19, 2023 | finance.yahoo.com

Calyxt Announces Stockholder Approval of Merger With Cibus

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

May 1, 2023 | finance.yahoo.com

Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 24, 2023 | finance.yahoo.com

Calyxt Completes One-for-Ten Reverse Stock Split

April 18, 2023 | finance.yahoo.com

Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

April 13, 2023 | finanznachrichten.de

Calyxt, Inc.: Calyxt Announces Effective Date of Reverse Stock Split

April 7, 2023 | finance.yahoo.com

Calyxt Announces Effective Date of Reverse Stock Split

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 9, 2023 | prnewswire.com

CALYXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Calyxt, Inc. - CLXT

March 6, 2023 | finance.yahoo.com

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

March 2, 2023 | finance.yahoo.com

Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update

February 21, 2023 | sg.finance.yahoo.com

Calyxt, Inc. (CLXT) stock historical prices & data – Yahoo Finance

February 15, 2023 | finance.yahoo.com

Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

January 18, 2023 | prnewswire.com

Shareholder Alert: Ademi LLP investigates whether Calyxt, Inc. has entered into a Fair Transaction with Cibus

January 17, 2023 | prnewswire.com

SHAREHOLDER ALERT: Weiss Law Investigates Calyxt, Inc.

January 17, 2023 | finance.yahoo.com

Calyxt Shares Surge On Merger Agreement Creating Agriculture-Focused Precision Gene Editing Company

January 17, 2023 | investorplace.com

Why Is Calyxt (CLXT) Stock Up 140% Today?

December 20, 2022 | finance.yahoo.com

Calyxt, Inc. (CLXT) Stock Historical Prices & Data - Yahoo Finance

November 20, 2022 | fool.com

Calyxt, Inc. (NASDAQ: CLXT)

November 18, 2022 | finance.yahoo.com

Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

November 17, 2022 | finance.yahoo.com

Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

November 9, 2022 | finance.yahoo.com

Calyxt Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 3, 2022 | finance.yahoo.com

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 3, 2022 | finance.yahoo.com

Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates

November 1, 2022 | finance.yahoo.com

Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing

October 27, 2022 | finance.yahoo.com

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

See More Headlines

Receive CLXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calyxt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/01/2023
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:CLXT
CUSIP: N/A
CIK: 1705843
Web: www.calyxt.com
Phone: (651) 683-2807
Fax: N/A
Employees: 48
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,890,000.00
Net Margins: -9,979.64%
Pretax Margin: -9,979.64%
Return on Equity: -259.69%
Return on Assets: -83.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.61
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $160,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,970,000
Free Float: 4,865,000
Market Cap: $31.31 million
Optionable: Not Optionable
Beta: 1.98

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Michael Allen Carr (Age 53)
Pres, CEO & Director
Comp: $543.56k
Mr. William F. Koschak (Age 54)
Chief Financial Officer
Comp: $356.74k
Dr. Travis J. Frey Ph.D. (Age 44)
Chief Technology Officer
Comp: $314.76k
Ms. Debra H. Frimerman (Age 43)
Gen. Counsel & Corp. Sec.
Comp: $334.08k
Dr. Daniel F. Voytas Ph.D. (Age 60)
Founder, Chief Science Officer & Chair of Scientific Advisory Board
Dr. Stephen M. Bravo
Chief Medical Officer
Mr. Gerry Nuovo
Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders

Rory B Riggs
Bought 200 shares on 6/1/2023
Total: $31,500.00 ($157.50/share)

CLXT Stock Analysis - Frequently Asked Questions

How were Calyxt's earnings last quarter?: Calyxt, Inc. (NASDAQ:CLXT) announced its quarterly earnings results on Monday, May, 1st. The company reported ($5.45) EPS for the quarter, missing analysts' consensus estimates of ($3.00) by $2.45. The business had revenue of $0.04 million for the quarter. Calyxt had a negative net margin of 9,979.64% and a negative trailing twelve-month return on equity of 259.69%.
When did Calyxt's stock split?: Calyxt shares reverse split before market open on Thursday, June 1st 2023. The 1-5 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of Calyxt own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Calyxt investors own include Cellectis (CLLS), Molecular Templates (MTEM), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Cypress Semiconductor (CY), Dynavax Technologies (DVAX), GW Pharmaceuticals (GWPH), Iovance Biotherapeutics (IOVA) and Invitae (NVTA).
When did Calyxt IPO?: Calyxt (CLXT) raised $101 million in an IPO on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

This page (NASDAQ:CLXT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Calyxt (CLXT) Stock Price, News & Analysis

About Calyxt Stock (NASDAQ:CLXT)

CLXT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

CLXT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info